

A close-up, profile view of a young child with dark skin and short hair, drinking from a clear glass. The child's face is in focus, and the background is a soft, out-of-focus orange-brown color. The text is overlaid on the right side of the image.

SAVING LIVES AND CREATING IMPACT

EU investment in poverty-related
neglected diseases

1

What has the EU invested in PRND R&D?

2

How have developing countries benefitted?

3

What is the return on investment for Europe?

EU Investment in PRND R&D

=

Health and prosperity in **developing countries**

+

Growth and competitiveness in the EU

- Levels of funding
- Nature of funding

- Health impact
- Economic impact
- Research capacity

- Jobs created
- Leveraged investment
- Scientific excellence
- Industrial competitiveness
- Health in the EU
- Integration

1

What has the EU invested in
PRND R&D?


The EU invests €341 million a year in
PRND R&D

15% OF ALL FUNDING
FOR PRND R&D

1


What has the EU invested in PRND R&D?

Top Funders




What has the EU invested in PRND R&D?

Member State Funding by GDP



Pharmaceutical Innovation



MDG 1 Eradicate Extreme Poverty and Hunger	MDG 2 Achieve Universal Primary Education	MDG 3 Promote Gender Equality and Empower Women	MDG 4 Reduce Child Mortality
MDG 5 Improve Maternal Health	MDG 6 Combat HIV/AIDS, Malaria and other diseases	MDG 7 Ensure Environmental Sustainability	MDG 8 A Global Partnership for Development

2

How have developing countries benefitted?

EU investment has contributed to the creation of **43 new PRND products**

2

How have developing countries benefitted?

MALARIA

INFECTS 216+ MILLION PEOPLE

KILLS AROUND 655,000 PEOPLE

KEY PHARMACEUTICAL INNOVATIONS

1. COARTEM

2. ASAQ

3. EUARTESIM

Image Credit: Anne Heslop Photography

2


How have developing countries benefitted?

359 products in development

43% involving European developers

FOR VACCINES ALONE, THERE ARE PROMISING CANDIDATES FOR BURULI ULCER, TUBERCULOSIS AND SCHISTOSOMIASIS

Key Developing Country Research Institutions in Africa & Asia




EU investment created more than
13,000 jobs

Two-thirds of Europe's PRND R&D funding is **invested back into Europe**


3

What is the return on investment for Europe?



What is the return on investment for Europe?

Top European PRND Research Institutes



6x

The European pharmaceutical industry invested six times more than the U.S. industry relative to annual revenues

**Increased PRND R&D investment
under Horizon 2020 will benefit both
developing countries and Europe**

EU Investment in
PRND R&D

$$= \begin{matrix} \text{Building Capacity in} \\ \text{Developing Countries} \\ + \\ \text{Quality Research} \end{matrix} + \begin{matrix} \text{Collaboration \&} \\ \text{partnerships} \\ + \\ \text{Integrating Industry} \end{matrix}$$

$$= \begin{matrix} \text{Health and prosperity} \\ \text{in } \text{developing} \\ \text{countries} \end{matrix} + \begin{matrix} \text{Growth and} \\ \text{competitiveness in} \\ \text{the EU} \end{matrix}$$

1

Increase investments in PRND R&D
including an increased commitment from
the EC under **Horizon 2020**

2

Retain and foster the **distinctive benefits of its approach** to funding PRND R&D

3

Improve specific aspects of its investment in PRND R&D, to ensure greater efficiency, impact and value

A close-up photograph of a young child with dark skin and short hair, smiling warmly. The child is leaning their arms against a thick, textured tree trunk. The background is softly blurred, showing more of the tree and a hint of an outdoor setting.

Thank you